Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: Integrated 2-year results

Archives of Neurology

Volumn 64, Issue 9, 2007, Pages 1292-1298

  Barkhof, Frederik ^a   Polman, Chris H ^a   Radue, Ernst Wilhelm ^b   Kappos, Ludwig ^b   Freedman, Mark S ^c   Edan, Gilles ^d   Hartung, Hans Peter ^e   Miller, David H ^f   Montalbán, Xavier ^g   Poppe, Peter ^a   De Vos, Marlieke ^a   Lasri, Fatiha ^a   Bauer, Lars ^h   Dahms, Susanne ^h   Wagner, Klaus ^h   Pohl, Christoph ^h,i   Sandbrink, Rupert ^h  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF OTTAWA   (Canada)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h BAYER PHARMA AG   (Germany)

ⁱ UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; INTERFERON BETA SERINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; CONTRAST MEDIA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 34548635873     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.9.1292     Document Type: Article

References (25)

1. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol. 2005;252(suppl 3):iii15-iii20.
2. Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol. 2001;8(1):27-35.
3. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-164.
4. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992;32(6):758-766.
5. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121(pt 1):3-24.
6. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
7. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285.
8. Paty DW, Li DK; UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):662-667.
9. Jacobs LD, Beck RW, Simon JH, et al; CHAMPS Study Group. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
10. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576-1582.
11. Barkhof F, van Waesberghe JH, Filippi M, et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon β-1b treatment. Brain. 2001;124(pt 7):1396-1402.
12. Filippi M, Rovaris M, Inglese M, et al. Interferon β-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9444):1489-1496.
13. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-1249.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231.
15. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 1997;49(6):1682-1688.
16. Molyneux PD, Miller DH, Filippi M, et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. Neuroradiology. 1999;41(12):882-888.
17. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. 2nd ed. Cary, NC: SAS Institute Inc; 2000.
18. Barkhof F, Tas MW, Frequin ST, et al. Limited duration of the effect of methyl-prednisolone on changes on MRI in multiple sclerosis. Neuroradiology. 1994;36(5):382-387.
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
20. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K; European Study Group on Interferon-β1b in secondary progressive multiple sclerosis. Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol. 1999;46(6):850-859.
21. Barkhof F, Held U, Simon JH, et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology. 2005;65(9):1447-1454.
22. Kappos L, Moeri D, Radue EW, et al; Gadolinium MRI Meta-analysis Group. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999;353(9157):964-969.
23. Barkhof F, McGowan JC, van Waesberghe JH, Grossman RI. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. J Neurol Neurosurg Psychiatry. 1998;64(suppl 1):S77-S79.
24. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol. 2001;49(6):793-796.
25. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46(5):747-754.